SEC Form 10-Q filed by Neumora Therapeutics Inc.
$NMRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $18.00 → $15.00 | Overweight → Neutral | JP Morgan |
| 10/1/2024 | $30.00 | Buy | H.C. Wainwright |
| 7/22/2024 | $23.00 | Buy | Needham |
| 7/8/2024 | $20.00 | Outperform | Mizuho |
| 12/12/2023 | $13.00 | Hold | Deutsche Bank |
| 10/10/2023 | $18.00 | Buy | BofA Securities |
| 10/10/2023 | $26.00 | Outperform | William Blair |
| 10/10/2023 | $21.00 | Overweight | JP Morgan |
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neumora Therape
WATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Company will participate in two investor conferences in November: Guggenheim's Inaugural Healthcare Innovation Conference: Members of management will participate in a fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Members of management will participate in a fireside chat on Monday, November 18, 2024, at 10:20 a.m. ET in New York, NY. A live webcast of each event will
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2024 to report its third quarter 2024 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participant
Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Neumora Therape
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Tuesday, November 12, 2024 to report its third quarter 2024 financial results and provide a business update. A live webcast of the event will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. Participant
Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $23.
Mizuho analyst Graig Suvannavejh initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Outperform rating and announces Price Target of $20.
10-Q - Neumora Therapeutics, Inc. (0001885522) (Filer)
8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)
144 - Neumora Therapeutics, Inc. (0001885522) (Subject)
JP Morgan downgraded Neumora Therapeutics from Overweight to Neutral and set a new price target of $15.00 from $18.00 previously
H.C. Wainwright initiated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $30.00
Needham initiated coverage of Neumora Therapeutics with a rating of Buy and set a new price target of $23.00
On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable securities expected to support operations into 2026 WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update. "2023 was a watershed year for Neumora as we
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya Pai Panandiker as chief commercial officer and a member of Neumora's executive team, reporting to Henry Gosebruch, president and chief executive officer. Ms. Pai Panandiker has more than 20 years of experience commercializing medicines in areas of significant unmet need, including the commercial launches of TRINTELLIX® (vortioxetine) and REXULTI® (brexpiprazole) for major depressive disorder (MDD) and schizophrenia. "I am excited to welcome Kaya to Neumora. As we progress t
WATERTOWN, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Jason Duncan as chief legal officer. Mr. Duncan will be a member of Neumora's Executive Team, reporting to Henry Gosebruch, chief executive officer, and will oversee all aspects of the Company's legal and compliance functions. "I am pleased to welcome Jason to Neumora. With his unique background that combines legal expertise with program strategy, I am confident that he will be a valuable addition to our team as we seek to deliver on our mission to redefine neuroscience drug dev
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)
SC 13G - Neumora Therapeutics, Inc. (0001885522) (Subject)